Regulatory Registration and Import
Cross-source consensus on Regulatory Registration and Import from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Risks & contraindications
Comparisons
Highlighted claims
- Registration is required before an anticancer medicine can be legally marketed and supplied. — Determinants of access to anticancer medicines in South Asia: a multimethod study
- Registration of WHO-listed anticancer medicines was more common than NEML inclusion in the studied countries. — Determinants of access to anticancer medicines in South Asia: a multimethod study
- Small markets, high treatment costs, and affordability constraints discouraged importers and multinational companies from registering or supplying oncology products. — Determinants of access to anticancer medicines in South Asia: a multimethod study
- All countries used special permission or need-based import pathways to address formal access gaps. — Determinants of access to anticancer medicines in South Asia: a multimethod study
- Import dependence created vulnerabilities involving border restrictions, cold chain logistics, inspection capacity, and medicine quality. — Determinants of access to anticancer medicines in South Asia: a multimethod study
- Need-based import pathways could expedite access but were costly, time-consuming, and unsuitable for urgent cancer treatment. — Determinants of access to anticancer medicines in South Asia: a multimethod study